Bariatric Surgery Market Overview The global bariatric surgery market is experiencing rapid growth, driven by the alarming rise in obesity and associated comorbidities across the world. Bariatric surg
Overweight and obesity represent addressable proximal drivers of chronic disease.1 The prevalence of overweight and obesity is increasing around the world; by 2050, projections indicate…
Nature Reviews Drug Discovery – Drug developers are re-advancing amylin analogues for obesity, two decades since the FDA approved the first of these hormone mimetics…
Acta Diabetologica – Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for treating type 2 diabetes and weight loss. There have been concerns that GLP-1RAs may…
Bariatric Surgery Market is expected reach USD 5.60billion at CAGR of 9.12% by 2034 owing to increased the demand for gastric bypass and rising minimally…
Genes & Immunity – Macrophage inhibition in the alleviation of nonalcoholic steatohepatitis caused by bariatric surgery
Background Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world …
GLP-1 receptor agonists may modestly reduce the risk for 14 obesity-related cancers, especially colorectal cancer, among adults with obesity and diabetes, new data suggest.
Reports allege UnitedHealth secretly paid nursing homes to reduce hospital transfers.
– The X post by Neil Floch MD highlights a New England Journal of Medicine (NEJM) study showing that higher BMI increases the risk of…
– The X post by Neil Floch MD shares a joint advisory from major health organizations, including the American College of Lifestyle Medicine, focusing on…
